 |
|
|
| |
PF-05221304 (PF'1304), a liver-targeted acetyl-CoA carboxylase inhibitor (ACCi), in adults with nonalcoholic fatty liver disease (NAFLD) demonstrates robust reductions in liver fat and ALT-Phase 2a, dose-ranging study
|
| |
| |
AASLD Boston, Massachusetts November 8-11 2019
Neeta B. Amin*, Santos Carvajal-Gonzalez*, Naresh Aggarwal, Theresa A. Tuthill*, Malgorzata Inglot, Arthur Bergman*, William Esler*
*Pfizer Inc. employees
|
| |
|
|
|
|
|
